News by subject: TRI

AppliedVR®, a medical device pioneer advancing a novel, virtual reality-based approach to medicine, and Kernel today announced a joint study measuring the impact of VR pain treatment on the brain. The study, which included a single-blind,...

Soligenix, Inc. (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today the formation of a Medical Advisory...

Beacon Therapeutics Holdings Limited ('Beacon Therapeutics' or 'the Company'), a leading ophthalmic gene therapy company with a mission to save and restore the vision of patients with blinding retinal diseases, yesterday announced the...

Following the successful filing of Intellectual Property (IP) for their applied platform technology targeting the endocannabinoid system (ECS), Tetra Pharm Technologies, is moving forward with its compound...

Orexa B.V., a Dutch life sciences company that is developing a new medicine that increases food intake and supports health in patients, announces that the first patient has been dosed in a Phase 2 clinical trial in the prevention of postoperative...

Zymedi announced today that the first in human dosage of ZMA001, a monoclonal antibody being developed as a first-in-class treatment for Pulmonary Arterial Hypertension (PAH) has been initiated. The placebo-controlled phase 1 trial designed to...

Revalesio, a clinical-stage pharmaceutical company developing treatments for acute and chronic...

Baked milk oral immunotherapy (BMOIT) is well tolerated and induces substantial desensitization to both baked and unheated milk according to new research being presented at the 2024 AAAAI Annual Meeting. 92% of participants tolerated approximately...

Johnson & Johnson today announced publication in the New England Journal of Medicine (NEJM) of the Phase 2b FRONTIER 1 trial results for JNJ-2113.1 JNJ-2113 is the...

Renibus Therapeutics® ("Renibus"), a clinical-stage biopharmaceutical company focusing on the prevention and treatment of cardio, renal and metabolic diseases, today announced that Frank Stonebanks, Renibus' Co-CEO, will present a company overview on...

Results support BLA submission in 2024 using the accelerated approval pathwayPrimary endpoint of patients achieving reduction in CSF biomarker of MPS II disease was met with statistical significance (p value of 0.00016) Patients treated with RGX-121...

CSA Medical Inc., a developer of medical devices advancing the power of liquid nitrogen spray cryotherapy, today announced its 500th Metered CryoSpray Procedure utilizing the RejuvenAir System. ...

The DeGregorio Family Foundation with support from the Torrey Coast Foundation Gastro Esophageal Investigator Network Initiative (GEMINI) has awarded $300,000 to Eric Smith, MD, PhD, and Andrew Aguirre, MD, PhD, both of Dana-Farber Cancer Institute,...

Genprex, Inc. ("Genprex" or the "Company") , a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the expansion of...

Completed enrollment in cohort 2 of the Phase I/II AFFINITY DUCHENNE® trial of RGX-202, a potential one-time AAV Therapeutic for the treatment of Duchenne that includes an optimized transgene for a novel microdystrophinNew three-month assessment in...

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology...

Biocomposites, an international medical devices company that engineers, manufactures and markets world leading products for use in infection management in bone and soft tissue, today announces the launch of two Phase II clinical trials of STIMULAN VG...

Invizius Limited...

IlluminOss Medical, offering a unique, minimally invasive technology for fracture repair and stabilization in geriatric and compromised bone, announced it has reached the important benchmark of enrolling over 200 patients in its global device...

Patients who were prescribed proton pump inhibitors (PPIs) in infancy demonstrated increased food allergy risk, according to new research being presented at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting, in Washington, DC...

SMC Laboratories, Inc. ("SMC Laboratories"), a non-clinical contract research organization (CRO) that provides consulting and contract services for pharmacology studies utilizing technology and know-how related to Metabolic dysfunction associated...

ShiraTronics, Inc., a pioneering clinical-stage medical device company, today proudly announced the successful conclusion of enrollment in their pilot study conducted in Australia for their minimally invasive, implantable migraine therapy....

Scientists at Camino Pharma, LLC, Sanford Burnham Prebys and University of California San Diego School of Medicine ­­received a $9-million grant (U01DA057847) from the National Institute on Drug Abuse (NIDA) at the National Institutes of Health...

Koning Health, a pioneer in advanced medical imaging technology, is proud to announce the successful showcasing of the Koning Vera Breast CT at the prestigious Arab Health exhibition in Dubai. Service provider, Unison Capital Investments, expertly...

GrayMatters Health (GMH), developer of digital self-neuromodulation therapies for mental health care, announces the publication of a peer-reviewed article in the Journal of Psychiatry Research demonstrating the safety and efficacy of its FDA-cleared...

Optimizing nutrition for premature infants remains an important focus in neonatal care. More than 20 peer-reviewed studies of 5,000+ preterm infants demonstrated that, compared to bovine milk-based fortifiers (BMBF), Prolacta Bioscience's human...

Through its Global Parkinson's Genetics Program (GP2), Aligning Science Across Parkinson's (ASAP) has awarded the Parkinson's Foundation a grant that will significantly expand its landmark international genetics...

A Stony Brook University team of researchers led by Gábor Balázsi, PhD, has identified DNA amplification as a major cause of drug resistance in engineered mammalian cell lines and has identified a novel approach to overcome it in those cells as well...

Redwood Scientific Technologies Inc. , ("Redwood" or "the Company"), a pioneering pharmaceutical company headquartered in New York, announced today that it has entered into an agreement with Jeeva Clinical Trials to launch a clinical effectiveness...

AvenCell Therapeutics, Inc., a leading clinical-stage cell therapy company focused on advancing both autologous and allogeneic switchable CAR-T cell therapies, today announced that it has dosed the first patient in a Phase IA study with AVC-201 for...

Lipocine Inc. , a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders by leveraging its proprietary platform, today announced that results from a multi-dose clinical study have confirmed the LPCN 1154 48-hour dosing...

Halia Therapeutics, a pharmaceutical company at the forefront of developing neuroinflammation-targeting drugs, and Canary Speech, a leader in artificial intelligence vocal biomarker technology, today announced a collaboration to revolutionize the way...

`The Foundation Fighting Blindness, the world's leading organization committed to finding treatments and cures for inherited retinal diseases and dry age-related macular degeneration, is launching a natural history study for people with gyrate...

Kyowa Kirin Co., Ltd. (TSE: 4151) today announced the enrollment of the first patient in a Phase 2 clinical trial, multi-center, randomized, double-masked, parallel group study of tivozanib eye drops (KHK4951). This study investigates the efficacy...

Research featured in Nature Communications highlights a novel approach that re-engineers a person's own immune cells to suppress the overactive immune system that occurs in lupus nephritis, a serious and potentially life-threatening inflammation of...

OX640 is Orexo's nasal epinephrine powder product for the acute treatment of severe allergic reactions including anaphylaxis, based on the company´s proprietary drug delivery platform, AmorphOX®The American Academy of Allergy, Asthma & Immunology...

Eupraxia...

Circufiber Inc., makers of the world's most scientifically advanced diabetic socks, announced today that it had achieved successful results in a clinical trial at Yale University's School of Medicine in New Haven, CT. The trial sought to prove that...

Genesis MedTech, a leading medical device company, today announced the completion of enrollment in its United States Early Feasibility Study (EFS) using its dedicated transcatheter aortic valve replacement (TAVR) system, J-Valvetm Transfemoral (TF)...

Study conducted by Meiji Seika Pharma in Japan Short communication follows previously published data in The Lancet Infectious Diseases demonstrating Immunological Non-Inferiority to Wuhan Strain and Superior Immunogenicity to Omicron BA.4/5 Variant...

Dilon Technologies Inc. announced today the enrollment of its first patient in the Prospective, Single-Arm, Multi-Center Pivotal Trial for its next generation MarginProbetm 2 product used in real-time margin assessment. "It is thrilling to witness...

Guangzhou Fermion Technology Co., Ltd. (Fermion), a clinical-stage AI-based drug discovery company that specializes in developing drugs for autoimmune diseases and pain management, is pleased to announce the approval of the Investigational New Drug...

Triumvira Immunologics, a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors, today announced that the first patient has been...

Technoderma Medicines, Inc. ("the Company"), a clinical stage biopharmaceutical company, is pleased to report that the Company has completed its Phase 2a clinical trial (NCT05802173) of TDM-105795 topical solution for Androgenetic Alopecia (AGA)....

iRegene Therapeutics Co., Ltd (iRegene) recently announced that NouvNeu001, the company's first innovative product, has completed the dosing for its first patient at Beijing Hospital, and the patient has also successfully concluded the observation...

Nipocalimab showed clinical efficacy in gMG, a chronic debilitating autoantibody disease where significant unmet patient need exists for efficacious, safe therapies that offer sustained disease control Nipocalimab is the first investigational...

ProfoundBio, a clinical-stage biotechnology company developing novel antibody-drug conjugate (ADC) therapeutics for cancer, today announced dosing has initiated in the Phase 1/2 first-in-human clinical trial of PRO1107 (NCT06171789)....

Genprex, Inc. ("Genprex" or the "Company") , a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that in January 2024, the first patient was enrolled and dosed in...

Palatin Technologies, Inc. , a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced database lock for its PL9643 MELODY-1 pivotal Phase 3...

Sirnaomics Ltd. (the "Company", Stock Code: 2257, together with its subsidiaries, the "Group" or "Sirnaomics"), a leading biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, presented the latest developments...